Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma-Future or the Past?
adjuvant therapy
immune checkpoint inhibitors
renal cell carcinoma
targeted therapy
tyrosine kinase inhibitors
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Aug 2022
03 Aug 2022
Historique:
received:
30
06
2022
revised:
28
07
2022
accepted:
30
07
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
epublish
Résumé
To review and discuss the literature on applying tyrosine kinase inhibitors (TKIs) in the treatment of metastasised renal cell carcinoma (mRCC). Medline, PubMed, the Cochrane database, and Embase were screened for randomised controlled trials, clinical trials, and reviews on treating renal cell carcinoma, and the role of TKI. Each substance's results were summarised descriptively. While TKI monotherapy is not currently recommended as a first-line treatment for metastasized renal cell carcinoma, TKIs are regularly applied to treat treatment-naïve patients in combination with immunotherapy. TKIs depict the first-choice alternative therapy if immunotherapy is not tolerated or inapplicable. Currently, seven different TKIs are available to treat mRCC. The importance of TKIs in a monotherapeutic approach has declined in the past few years. The current trend toward combination therapy for mRCC, however, includes TKIs as one significant component of treatment regimens. We found that to remain applicable to ongoing studies, both when including new substances and when testing novel combinations of established drugs. TKIs are of major importance for the treatment of renal cancer now, as well as for the foreseeable future.
Sections du résumé
BACKGROUND
BACKGROUND
To review and discuss the literature on applying tyrosine kinase inhibitors (TKIs) in the treatment of metastasised renal cell carcinoma (mRCC).
MATERIALS AND METHODS
METHODS
Medline, PubMed, the Cochrane database, and Embase were screened for randomised controlled trials, clinical trials, and reviews on treating renal cell carcinoma, and the role of TKI. Each substance's results were summarised descriptively.
RESULTS
RESULTS
While TKI monotherapy is not currently recommended as a first-line treatment for metastasized renal cell carcinoma, TKIs are regularly applied to treat treatment-naïve patients in combination with immunotherapy. TKIs depict the first-choice alternative therapy if immunotherapy is not tolerated or inapplicable. Currently, seven different TKIs are available to treat mRCC.
CONCLUSIONS
CONCLUSIONS
The importance of TKIs in a monotherapeutic approach has declined in the past few years. The current trend toward combination therapy for mRCC, however, includes TKIs as one significant component of treatment regimens. We found that to remain applicable to ongoing studies, both when including new substances and when testing novel combinations of established drugs. TKIs are of major importance for the treatment of renal cancer now, as well as for the foreseeable future.
Identifiants
pubmed: 35954446
pii: cancers14153777
doi: 10.3390/cancers14153777
pmc: PMC9367545
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Lancet Oncol. 2009 Aug;10(8):757-63
pubmed: 19615940
Cancer Res. 2006 Sep 15;66(18):9134-42
pubmed: 16982756
J Med Chem. 2014 Sep 25;57(18):7577-89
pubmed: 25148209
Cancer Med. 2022 Mar 18;:
pubmed: 35304832
Basic Clin Pharmacol Toxicol. 2015 Mar;116(3):216-21
pubmed: 25495944
JAMA Oncol. 2017 Sep 01;3(9):1249-1252
pubmed: 28278333
Eur Urol Focus. 2022 Mar;8(2):514-521
pubmed: 33714725
N Engl J Med. 2021 Aug 19;385(8):683-694
pubmed: 34407342
Cancer Lett. 2013 Oct 28;340(1):97-103
pubmed: 23856031
J Clin Oncol. 2020 Dec 1;38(34):4064-4075
pubmed: 33052759
N Engl J Med. 2021 Mar 4;384(9):829-841
pubmed: 33657295
Lancet Oncol. 2015 Nov;16(15):1473-1482
pubmed: 26482279
Lancet Oncol. 2013 May;14(6):552-62
pubmed: 23598172
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
JAMA Oncol. 2020 Aug 1;6(8):1247-1255
pubmed: 32469384
N Engl J Med. 2013 Aug 22;369(8):722-31
pubmed: 23964934
ESMO Open. 2020 Nov;5(6):e001079
pubmed: 33246931
N Engl J Med. 2021 Apr 8;384(14):1289-1300
pubmed: 33616314
J Clin Oncol. 2010 Feb 20;28(6):1061-8
pubmed: 20100962
Clin Genitourin Cancer. 2020 Aug;18(4):e374-e385
pubmed: 32466961
Eur Urol. 2021 Oct;80(4):393-397
pubmed: 34074559
Eur Urol Focus. 2022 Feb 19;:
pubmed: 35193819
Ann Oncol. 2011 Aug;22(8):1812-23
pubmed: 21324953
Lancet Oncol. 2022 Jun;23(6):768-780
pubmed: 35489363
Lancet Oncol. 2013 Dec;14(13):1287-94
pubmed: 24206640
J Clin Oncol. 2017 Feb 20;35(6):591-597
pubmed: 28199818
Curr Treat Options Oncol. 2019 May 3;20(5):44
pubmed: 31054006
Oncologist. 2019 Aug;24(8):e702-e708
pubmed: 30902918
Cancer Cell Microenviron. 2015;2(1):
pubmed: 26005708
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Oncologist. 2010;15(6):539-47
pubmed: 20511320
Ann Oncol. 2020 Aug;31(8):1030-1039
pubmed: 32339648
Lancet Oncol. 2020 Jan;21(1):95-104
pubmed: 31810797
Adv Anat Pathol. 2019 Mar;26(2):124-132
pubmed: 30507616
Curr Opin Urol. 2019 Nov;29(6):636-642
pubmed: 31348025
J Clin Oncol. 2009 Mar 10;27(8):1280-9
pubmed: 19171708
J Clin Oncol. 2017 Dec 10;35(35):3916-3923
pubmed: 28902533
Pharmacol Res. 2015 Oct;100:1-23
pubmed: 26207888
J Clin Oncol. 2013 Oct 20;31(30):3791-9
pubmed: 24019545
Curr Cancer Drug Targets. 2010 Aug;10(5):462-83
pubmed: 20384577
Eur Urol. 2015 Nov;68(5):837-47
pubmed: 25952317
Cancer. 2010 Mar 1;116(5):1272-80
pubmed: 20082451
Front Oncol. 2020 May 07;10:664
pubmed: 32457838
Lancet Oncol. 2020 Dec;21(12):1563-1573
pubmed: 33284113
Cancer Sci. 2018 Apr;109(4):1207-1219
pubmed: 29446853
N Engl J Med. 2007 May 31;356(22):2271-81
pubmed: 17538086
Lancet. 2016 May 14;387(10032):2008-16
pubmed: 26969090
Lancet Oncol. 2016 Jul;17(7):917-927
pubmed: 27279544
Lancet. 2011 Dec 3;378(9807):1931-9
pubmed: 22056247
Expert Rev Anticancer Ther. 2017 Feb;17(2):129-142
pubmed: 27967249
Oncologist. 2019 Apr;24(4):491-497
pubmed: 30867244
Expert Opin Drug Metab Toxicol. 2012 Feb;8(2):259-70
pubmed: 22248343
Eur J Cancer. 2020 Apr;129:107-116
pubmed: 32146304
N Engl J Med. 2007 Jan 11;356(2):125-34
pubmed: 17215530
Ann Oncol. 2018 Dec 1;29(12):2371-2378
pubmed: 30346481
Cancer Chemother Pharmacol. 2016 Aug;78(2):325-32
pubmed: 27324136
Eur Urol. 2015 May;67(5):913-24
pubmed: 25616710
Target Oncol. 2022 Jan;17(1):61-68
pubmed: 34894318
Oncogene. 2000 Nov 20;19(49):5548-57
pubmed: 11114734
Cancer Res. 2004 Oct 1;64(19):7099-109
pubmed: 15466206
J Geriatr Oncol. 2021 Jun;12(5):820-826
pubmed: 33674246
Eur Urol. 2018 Jan;73(1):62-68
pubmed: 28967554
J Clin Oncol. 2014 May 10;32(14):1412-8
pubmed: 24687826
J Clin Oncol. 2009 Aug 1;27(22):3584-90
pubmed: 19487381
Oncologist. 2017 Jan;22(1):41-52
pubmed: 27807302